Analysis of neutralizing antibodies to COVID-19 inactivated or subunit recombinant vaccines in hospitalized patients with liver dysfunction.
Analysis of neutralizing antibodies to COVID-19 inactivated or subunit recombinant vaccines in hospitalized patients with liver dysfunction.
复制标题
肝功能不全住院患者接种 COVID-19 疫苗后抗体反应分析
DOI：
10.3389/fimmu.2023.1084646
复制
发表时间：
2023
影响因子：
7.3
通讯作者：
Zhong, Shan
中科院分区：
文献类型：
--
作者：
Li, Hu;Li, Shiyin;Xu, Pan;Wang, Xiaohao;Deng, Huan;Lei, Yu;Zhong, Shan
肝功能障碍后COVID-19疫苗接种后的中和抗体（nab）反应尚不清楚。在本研究中，我们评估了住院的肝功能障碍患者在COVID-19疫苗接种后nab的反应。在这项纵向随访的横断面研究中，我们招募了符合条件的肝功能障碍患者和接种了全程COVID-19疫苗的健康志愿者。在入院时和治疗后采集血样进行nab检测。多元回归分析评价影响抗体反应的独立危险因素。共纳入137例患者和134例健康对照（HC）。患者血清nab阳性（65.7% vs 80.6%, p<0.01）和滴度（3.95 vs 4.94 log2 AU/ml, p<0.001）均显著低于HC。患者抗体滴度下降明显快于HC。在校正了潜在的混杂因素后，在多元回归分析中，男性（优势比[OR]: 0.17； 95%可信区间[CI]: 0.06, 0.46; p<0.001）和严重肝损害（OR: 0.30; 95% CI: 0.12, 0.71; p<0.01）与nab血清阳性概率的降低显著相关。男性（β =-1.18; 95% CI: -1.73,-0.64）和慢性肝病（β =-1.45; 95% CI: -2.13, -0.76）与nab滴度降低显著相关。在26例肝功能衰竭患者中，人工肝血浆置换后抗体血清阳性（53.8% vs 84.6%, p<0.05）和滴度（3.55 vs 4.32 log2 AU/ml, p<0.001）均未降低而升高。在肝功能障碍患者中，nab对COVID-19灭活疫苗或亚单位重组疫苗的反应减弱。此外，男性、严重肝损伤和慢性肝病患者抗体反应差的风险增加。
The neutralizing antibodies (NAbs) response after COVID-19 vaccination after liver dysfunction is unclear. In this study, we evaluated the NAbs response after COVID-19 vaccination in hospitalized patients suffering from liver dysfunction. In this cross-sectional study with longitudinal follow-up, we enrolled eligible patients with liver dysfunction and healthy volunteers with full-course COVID-19 vaccination. Blood samples were collected for the NAbs testing at the time of admission and after treatment. Multiple regression analysis to assess independent risk factors affecting NAbs response. A total of 137 patients and 134 healthy controls (HC) were enrolled. Both seropositivity (65.7% vs 80.6%, p<0.01) and titer (3.95 vs 4.94 log2 AU/ml, p<0.001) of NAbs in patients were significantly lower than that in HC. The decrease of antibody titer in patients was significantly faster than that in HC. After adjusting for potential confounding factors, males (odds ratio [OR]: 0.17; 95% confidence interval [CI]: 0.06, 0.46; p<0.001) and severe liver damage (OR: 0.30; 95% CI: 0.12, 0.71; p<0.01) were significantly associated with reduction of the probability of NAbs seropositivity in the multiple regression analysis. Males (β =-1.18; 95% CI: -1.73,-0.64) and chronic liver diseases (β =-1.45; 95% CI: -2.13, -0.76) were significantly associated with lower NAbs titers. In 26 patients with liver failure, both antibody seropositivity (53.8% vs 84.6%, p<0.05) and titer (3.55 vs 4.32 log2 AU/ml, p<0.001) did not decrease but increased after artificial liver plasmapheresis. NAbs response to COVID-19 inactivated or subunit recombinant vaccines was waning in patients with liver dysfunction. Moreover, patients with male sex, severe liver injury and chronic liver diseases have an increased risk of poor antibody responses.
登录
查看更多内容
影响因子：
12.8
作者：
Efe, Cumali;Tascilar, Koray;Gerussi, Alessio;Bolis, Francesca;Lammert, Craig;Ebik, Berat;Stattermayer, Albert Friedrich;Cengiz, Mustafa;Gokce, Dilara Turan;Cristoferi, Laura;Peralta, Mirta;Massoumi, Hatef;Montes, Pedro;Cerda, Eira;Rigamonti, Cristina;Yapali, Suna;Adali, Gupse;Caliskan, Ali Riza;Balaban, Yasemin;Eren, Fatih;Eskazan, Tugce;Barutcu, Sezgin;Lytvyak, Ellina;Zazueta, Godolfino Miranda;Kayhan, Meral Akdogan;Heurgue-Berlot, Alexandra;De Martin, Eleonora;Yavuz, Ahmet;Biyik, Murat;Narro, Graciela Castro;Duman, Serkan;Hernandez, Nelia;Gatselis, Nikolaos K.;Aguirre, Jonathan;Idilman, Ramazan;Silva, Marcelo;Mendizabal, Manuel;Atay, Kadri;Guzelbulut, Fatih;Dhanasekaran, Renumathy;Montano-Loza, Aldo J.;Dalekos, George N.;Ridruejo, Ezequiel;Invernizzi, Pietro;Wahlin, Staffan
通讯作者：
Wahlin, Staffan
DOI：
10.1016/s2665-9913(21)00222-8
发表时间：
2021-11
期刊：
The Lancet. Rheumatology
影响因子：
--
作者：
Boekel L;Steenhuis M;Hooijberg F;Besten YR;van Kempen ZLE;Kummer LY;van Dam KPJ;Stalman EW;Vogelzang EH;Cristianawati O;Keijzer S;Vidarsson G;Voskuyl AE;Wieske L;Eftimov F;van Vollenhoven R;Kuijpers TW;van Ham SM;Tas SW;Killestein J;Boers M;Nurmohamed MT;Rispens T;Wolbink G
通讯作者：
Wolbink G
影响因子：
7.3
作者：
Li Z;Xiang T;Liang B;Deng H;Wang H;Feng X;Quan X;Wang X;Li S;Lu S;Yang X;Wang B;Zelinskyy G;Trilling M;Sutter K;Lu M;Dittmer U;Yang D;Zheng X;Liu J
通讯作者：
Liu J
自身免疫性肝病患者免疫抑制剂与 SARS-CoV-2 疫苗抗体反应不良之间的关联
影响因子：
7.3
作者：
Li, Hu;Wang, Yuting;Ao, Ling;Ke, Mingxia;Chen, Zhiwei;Chen, Min;Peng, Mingli;Ling, Ning;Hu, Peng;Cai, Dachuan;Zhang, Dazhi;Ren, Hong
通讯作者：
Ren, Hong
影响因子：
13.8
作者：
Steele, Molly K.;Couture, Alexia;Reed, Carrie;Iuliano, Danielle;Whitaker, Michael;Fast, Hannah;Hall, Aron J.;MacNeil, Adam;Cadwell, Betsy;Marks, Kristin J.;Silk, Benjamin J.
通讯作者：
Silk, Benjamin J.